)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
Foghorn Therapeutics
Foghorn Therapeutics (FHTX) investor relations material
Foghorn Therapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary30 Apr, 2026
Executive summary
Annual meeting scheduled for June 24, 2026, to be held virtually for stockholders of record as of April 27, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of three Class III directors for a three-year term: Douglas Cole, M.D., Balkrishan (Simba) Gill, Ph.D., and B. Lynne Parshall.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory vote to approve the compensation of named executive officers.
Advisory vote on the frequency of future advisory votes on executive compensation, with the board recommending a 1-year frequency.
Board of directors and corporate governance
Board recommends voting FOR all director nominees and FOR all proposals, including a 1-year frequency for say-on-pay votes.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Foghorn Therapeutics
- Advancing oncology pipeline with strong financial backing and key clinical milestones ahead.FHTX
TD Cowen 46th Annual Health Care Conference4 May 2026 - Annual meeting to vote on directors, auditor, executive pay, and major governance matters.FHTXProxy filing30 Apr 2026
- Pipeline leverages chromatin biology with strong Lilly partnership and promising oncology assets.FHTXInvestor presentation11 Mar 2026
- Clinical pipeline advances, reduced net loss, and $50M financing extend cash runway into 2028.FHTXQ4 202511 Mar 2026
- SMARCA2 and CBP/EP300 programs advance, with key clinical milestones expected this year.FHTXGuggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026
- Selective chromatin regulator targeting advances, with promising clinical and pipeline progress.FHTXGuggenheim Securities 2nd Annual Healthcare Innovation Conference3 Feb 2026
- Advancing chromatin-targeted oncology pipeline with key partnerships and strong financial runway.FHTXMorgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026
- Advancing chromatin-targeted therapies with clinical and preclinical programs for major cancer indications.FHTXJefferies London Healthcare Conference 202413 Jan 2026
- Advancing chromatin-targeted therapies in AML and SMARCA4-mutant cancers, with new ARID1B focus.FHTX7th Annual Evercore ISI HealthCONx Conference12 Jan 2026
Next Foghorn Therapeutics earnings date
Q1 202613 May, 2026
Foghorn Therapeutics
Next Foghorn Therapeutics earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage